2026.01. 30 本文字数：3193，阅读时长大约5分钟 作者 | 第一财经 吴斯旻 随着AI制药渡过最初的技术可行性验证阶段，生物医药领域的技术和资本加速向这一赛道聚集，却 也加剧了不同研发方向的资源分化：相较于因AI加持而更加火热的肿瘤、自身免疫疾病的药物研 发，在结核、疟疾以及尼帕病毒等原本就较为冷清的传染病药物研发中，AI制药项目启动寥寥。 但AI驱动抗病毒新药研发虽然冷门却是刚需。当前，公共卫生领域创新药物研发面临研发投入远 超"双十周期"（指一款创新药物从启动研发到最终上市，平均研发周期超过10年，研发成本超过10 亿美元），商业回报不确定性更强，靶点稀缺，病毒易变异并产生耐药性，动物模型稀缺且预测性 差，药物毒性和安全性挑战高等诸多堵点，为此，在受访业界人士看来，AI大模型对于这一赛道的 赋能效益或会更加显著。 AI如何生成"千里马"新药分子 "从AI制药平台本身而言，它可以用来设计传染病药物的AI大分子模型，也可以用于肿瘤、神经退行 性疾病、罕见疾病等研发领域，关键在于投入的优先级。"全球健康药物研发中心（GHDDI）数据科 学部负责人郭晋疆在接受第一财经专访时说。 GHDDI是由北京市 ...

Group 1 - The integration of AI in medicine and engineering is accelerating drug development, enhancing clinical precision, and driving innovation in the healthcare industry, providing stronger technological support for public health [1] - The newly launched AI drug development platform "AI Kongming" has shown significant improvements in candidate molecule hit rates and optimization efficiency, achieving several times to tens of times better results compared to traditional processes [2] - AI technologies are increasingly applied across various medical fields, including drug development, medical imaging, disease diagnosis, and health monitoring, demonstrating a broad impact on healthcare [3] Group 2 - Pharmaceutical companies like Shijiazhuang Pharmaceutical Group and Heng Rui Medicine are establishing AI research departments to expedite drug target discovery and clinical trial processes [4] - Platforms for innovation in medical-engineering integration are being developed, such as the Suzhou Industrial Park's platform for transforming innovative results and Haier's health technology innovation platform, aimed at breaking down barriers between data, disciplines, and institutions [5] - National policies are being introduced to promote the deep integration of new information technologies with the pharmaceutical industry, including guidelines that recognize AI-assisted diagnosis as an extension of pathological diagnosis [5]

Group 1 - The integration of AI in healthcare is accelerating drug development, enhancing clinical precision, and driving innovation in the medical industry, providing stronger technological support for public health [1][2] - The AI platform "AI Kongming" has been launched, offering free access to databases related to global health challenges, significantly improving candidate molecule hit rates and optimization efficiency by several times compared to traditional processes [1][2] - AI technologies are increasingly applied across various medical fields, including drug development, medical imaging, disease diagnosis, and health monitoring, showcasing their versatility and potential impact [2][3] Group 2 - Major pharmaceutical companies like Shijiazhuang Pharmaceutical Group and Hengrui Medicine are establishing AI research departments to accelerate drug target discovery and clinical trial processes [3][4] - The establishment of innovation platforms, such as the one in Suzhou Industrial Park, aims to facilitate the transformation of medical and engineering innovations, breaking down barriers between data, disciplines, and institutions [4][5] - National policies are being introduced to promote the integration of new information technologies with the pharmaceutical industry, enhancing the application of AI in clinical settings [4][5]

Core Insights - The pharmaceutical industry is experiencing a transformation driven by artificial intelligence (AI), which is reshaping drug discovery and development processes, making it a focal point for global technological and pharmaceutical innovation [1][4][14] - AI-driven drug development is moving from concept validation to early value realization, attracting significant attention from capital markets, policymakers, and research institutions [1][5][14] Investment and Financing Activity - The global AI pharmaceutical sector has over 350 companies, with at least 101 based in China, most of which are in the early stages of development [5] - In 2023, there were nearly 80 investment events related to AI pharmaceuticals globally, with at least 31 occurring in China, indicating a growing interest from investors [5][6] - The trend of increasing investment in AI pharmaceuticals has been consistent over the past three years, with the number of financing events rising from 19 in 2023 to 31 in 2024, matching previous years' levels [5] Technological Advancements - AI technologies, particularly large language models and generative AI, are redefining traditional drug development paradigms, which have historically been time-consuming and costly [4][7] - New AI models are capable of generating drug molecules with potential biological activity tailored to specific diseases, significantly enhancing the drug design process [4][8] Collaboration and Partnerships - The AI pharmaceutical landscape is witnessing an increase in collaborations, with over 30 partnerships established in 2023 between multinational companies and AI-related firms, valued at approximately $10 billion [10][11] - Major pharmaceutical companies are shifting from solely in-house AI tool development to a mixed strategy that includes external collaborations, reflecting a significant change in industry mindset [10] Data Challenges - The success of AI in drug development is heavily reliant on the availability of high-quality data, which remains a challenge due to proprietary data restrictions within pharmaceutical companies [12][13] - The concept of "data capitalization" is proposed as a solution to enhance data sharing among companies, which could facilitate more effective AI model development [13] Future Outlook - As AI pharmaceutical models improve and data governance frameworks become more robust, AI-driven drug development is expected to become a key indicator of national pharmaceutical innovation competitiveness [14]

Core Insights - The pharmaceutical industry is experiencing a transformation driven by artificial intelligence (AI), which is reshaping drug discovery and development processes, making it a focal point for global technological and pharmaceutical innovation [1][3] - AI-driven drug development is moving from concept validation to early value realization, attracting significant attention from capital markets, policymakers, and research institutions [1][4] - The integration of AI technologies, particularly generative AI and multimodal models, is expected to overcome traditional drug development challenges, enhancing the efficiency and success rates of new drug candidates [3][4] Investment and Financing Activity - The global AI pharmaceutical sector has over 350 companies, with at least 101 based in China, most of which are in the early stages of development [4] - In 2023, there were nearly 80 investment events related to AI pharmaceuticals globally, with at least 31 occurring in China, indicating a strong upward trend in investment activity [4][5] - The financing round for InSilico Medicine raised $123 million, marking a significant investment in the AI pharmaceutical space [5] Collaboration and Partnerships - The trend of collaboration in AI drug development is increasing, with over 30 partnerships established between multinational corporations and AI companies in 2023, valued at approximately $10 billion [7][8] - Major pharmaceutical companies are shifting from solely developing in-house AI tools to exploring hybrid strategies and external solutions, reflecting a significant change in industry mindset [7][8] Data Challenges - The AI pharmaceutical sector faces challenges related to data scarcity, as high-quality data necessary for effective model development is often locked within proprietary corporate databases [9][10] - The concept of "data capitalization" is proposed as a solution to enhance data sharing among companies, which could facilitate better AI model development [10][11] Technological Advancements - The rapid development of cloud computing capabilities by tech giants like Amazon, Google, and Microsoft is providing essential computational power for pharmaceutical companies, alleviating some constraints on data and model development [11] - Continuous improvements in model performance and data governance are expected to position AI pharmaceuticals as a key measure of national pharmaceutical innovation competitiveness [11]

Group 1 - OpenAI launched GPT-5.2, which includes Instant, Thinking, and Pro modes, as a response to Google's Gemini 3, indicating a competitive shift in the AI landscape [2] - Disney agreed to invest $1 billion in OpenAI and became the first major content licensing partner for OpenAI's short video generation platform, Sora, which will utilize over 200 characters from Disney franchises [2] - The "Film Hurricane" team has joined Alibaba's international platform to leverage AI for expanding into overseas markets, receiving collaboration interest from over 30 countries [2] Group 2 - The AI drug discovery platform "AI Kongming," developed by a non-profit organization, was launched in Beijing, covering the entire drug discovery process from target structure analysis to drug design [2]

Group 1 - The article discusses the recent announcement by artist Fan Zeng, who declared a complete severance of ties with his daughter and stepson while entrusting all personal and business affairs to his wife, Xu Meng. This decision is linked to the establishment of a new company, "Shiyi Fan Zeng (Beijing) Cultural and Art Co., Ltd." [1] - The new company is expected to handle all commercial operations related to Fan Zeng's art, indicating a significant shift in his business strategy and personal relationships [1]. Group 2 - The stock of Moer Thread, known as the "first domestic GPU stock," surged by 723% within five trading days after its debut on the STAR Market, reaching a market capitalization of 442.3 billion yuan [2][3]. - As of December 11, the stock price hit a high of 941.08 yuan, with a single-day increase of 28.04%, indicating strong market interest and a potential redefinition of valuation logic in the tech sector [2][3]. Group 3 - Meta is reportedly using Alibaba's Qwen model for distillation optimization in training its new AI model, "Avocado," which is expected to be released in spring 2026 [4]. - The article highlights the recognition of AI pioneers, including Elon Musk and others, as TIME magazine's "Person of the Year," emphasizing the significant impact of AI on various sectors [4]. Group 4 - Bilibili (B Station) has denied rumors regarding a mandatory membership requirement for all video content starting March 1, 2026, and stated that legal action will be taken against those spreading false information [6]. - The company aims to maintain a sustainable community ecosystem and ensure quality content creation [6]. Group 5 - Heytea has closed over 650 stores in a year, with a significant reduction in total store count from 4,610 to 3,930, reflecting a 15.41% year-on-year decline [8][9]. - The company previously announced a halt on franchise applications to avoid price wars and focus on user experience and brand integrity [9]. Group 6 - OPPO is restructuring its AI department, merging several projects into a new initiative called "Super Xiaobu," aimed at enhancing its AI capabilities [8]. - The company is focusing on integrating its AI technologies to improve product offerings and user experience [8]. Group 7 - Disney has agreed to invest $1 billion in OpenAI and has authorized the use of its iconic characters for AI-generated short videos, marking a significant partnership in the AI content creation space [11]. - This agreement allows OpenAI to leverage Disney's extensive character library while excluding the use of actor likenesses or voices [11]. Group 8 - The AI drug development platform "AI Kongming" has been launched to address global health challenges, aiming to enhance the efficiency and success rate of drug development processes [19]. - This platform is the first of its kind in China, focusing on diseases like malaria and tuberculosis [19]. Group 9 - China's automotive industry has seen production and sales exceed 31 million units in the first 11 months of the year, with a notable increase in new energy vehicle production and exports [20]. - The data indicates a strong growth trajectory in the automotive sector, with a year-on-year increase of over 10% in both production and sales [20].

Group 1 - Meta's new model Avocado may become closed-source and is expected to launch in spring next year [1] - Beijing Humanoid Robot Innovation Center has introduced the first fully autonomous unmanned tour guide solution in the country [1] - The Chinese self-developed AI pharmaceutical platform "AI Kongming" has been released [1] Group 2 - Lingchu Intelligent has launched the world's first embodied native human data collection solution, Psi-SynEngine [1] - Zhipu has released an industrial-grade speech synthesis system, GLM-TTS [1] - Microsoft's CEO announced that the company plans to release a new intelligent AI model on Friday [1]